Table 2.
Different oncological treatment protocols in the included studies.
| Studies | Study interval | Histotype | Number of patients | Oncological treatment protocols | |
|---|---|---|---|---|---|
| Yang et al. (27) | 2006 | 2012 | SCLC | 320 | PB+E |
| Osterlind et al. (28) | 1973 | 1981 | SCLC | 815 | L+C+M, L+C+M+V, L+C+M+V+D+E alternating, L+C+E+V +/- radiotherapy |
| Zarzecka et al. (29) | 2010 | 2012 | NSCLC | 290 | NSCLC – PB and third generation drugs, in SCLC with PB+E |
| Hermes et al. (30) | 2004 | 2008 | SCLC | 395 | PB+E |
| Wang et al. (31) | 2006 | 2013 | SCLC | 631 | PB+E |
| Berardi et al. (32) | 2006 | 2015 | NSCLC | 433 | PB, Non-PB, EGFR- TKI |
| Sengupta et al. (33) | 2011 | 2012 | NSCLC | 116 | unknown |
| Kobayashi et al. (34) | 2000 | 2009 | NSCLC | 386 | resection+ postoperative adjuvant treatment |
| Fucá et al. (35) | 2013 | 2018 | NSCLC | 197 | PD-1/PDL-1 inhibitors |
| Alamoudi (36) | 2004 | 2008 | LC | 114 | unkown |
| Hansen et al. (37) | 1995 | 2005 | SCLC | 453 | PB+E |
| Svaton et al. (38) | 2006 | 2013 | NSCLC | 544 | erlotinib |
| Allan et al. (39) | 1982 | 1988 | SCLC | 411 | M+CCVVP+/-D,+/-radiotherapy and PCI or VI+E |
| Li et al. (40) | 2007 | 2014 | NSCLC | 1083 | resection |
| Osterlind et al. (41) | 1973 | 1981 | SCLC | 874 | L+C+M,L+C+M+V, L+C+M+V+D+E, +/- radiotherapy |
| Doshi et al. (42) | 2010 | 2014 | NSCLC | 257 | PB+PM |
| Johnson et al. (43) | 1989 | 1992 | LC | 50 | PB+E |
| Sagman et al. (44) | 1976 | 1986 | SCLC | 614 | Different protocols: C+D+V, L+P+M, PB+E |
| Jacot et al. (45) | 2003 | 2006 | NSCLC | 301 | surgery, PB, second line, palliative |
| Hong et al. (46) | 2000 | 2009 | SCLC | 999 | chemotherapy(etoposide)+/-radiotherapy+/-surgery |
| Maestu et al. (47) | 1981 | 1993 | SCLC | 341 | different protocols:C+D+V, PB and others+/- radio |
| Kawahara et al. (48) | 1985 | 1988 | SCLC | 286 | different protocols: C+D+V, P+E, or C+D+V+P+E |
| Cerny et al. (49) | 1979 | 1985 | SCLC | 407 | different protocols:C+M+E+/-radiotherapy |
| Ma et al. (50) | 2000 | 2007 | SCLC | 158 | unknown |
| Umemura et al. (51) | 1981 | 2001 | SCLC | 163 | PB or alternating chemotherapy |
| Jacot et al. (52) | 1992 | 1998 | NSCLC | 231 | radiotherapy, chemotherapy, surgery and their combinations |
| Rechnitzer et al. (53) | 1987 | 1990 | NSCLC | 229 | chemotherapy+radiotherapy |
| Bose et al. (54) | 2008 | 2008 | NSCLC | 40 | PB+PC for NSCLC, PB+E for SCLC |
| Rinaldi et al. (55) | 2006 | 2017 | NSCLC | 647 | PB or EGFR-TKI |
| Chan et al. (56) | 2011 | 2016 | LC | 624 | unknown |
| Huang et al. (57) | 2011 | 2018 | SCLC | 358 | PB+ E and others |
SCLC, small cell lung cancer, NSCLC, Non-small cell lung cancer, LC, every lung cancer histotype, PB, Platinum-based preparations, PC, paclitaxel, PM, pemetrexed, L, lomustine, C, cyclophosphamide, M, methotrexate, V, vincristine, D, doxorubicine, E, etoposide, P, procarbazine, VI, vindesine, PCI, prophilactic cranial irradiation, EGFR, epidermal growth factor receptor, TKI, tyrosine kinase inhibitors.